In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sequencing costs come down, while patients’ wait continues

This article was originally published in Scrip

Executive Summary

Last Monday, the publication of a letter in Nature Biotechnology described the first “single-molecule sequencing of an individual human genome”, using a third-generation sequencing instrument by Helicos. While the sequencing of a whole human genome per se is no longer extraordinary, it is generally agreed that to make a patient’s DNA data available for a personalised medicine approach, the effort, time and money invested in sequencing a single person’s genome need to come down considerably.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts